ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Oncology
ESPS manuscript NO: 28882
Title: Targeted therapies in breast cancer: New challenges to fight against resistance
Reviewer’s code: 02104609
Reviewer’s country: Canada
Science editor: Fang-Fang Ji
Date sent for review: 2016-07-21 14:18
Date reviewed: 2016-07-22 11:20

<table>
<thead>
<tr>
<th>CLASSIFICATION</th>
<th>LANGUAGE EVALUATION</th>
<th>SCIENTIFIC MISCONDUCT</th>
<th>CONCLUSION</th>
</tr>
</thead>
<tbody>
<tr>
<td>[  ] Grade B: Very good</td>
<td>[ ] Grade B: Minor language polishing</td>
<td>[ ] The same title</td>
<td>[ Y] High priority for publication</td>
</tr>
<tr>
<td>[  ] Grade C: Good</td>
<td>[ ] Grade C: A great deal of language polishing</td>
<td>[ ] Duplicate publication</td>
<td>[ ] Rejection</td>
</tr>
<tr>
<td>[  ] Grade D: Fair</td>
<td>[ ] Grade D: Rejected</td>
<td>[ Y] No</td>
<td>[ ] Minor revision</td>
</tr>
<tr>
<td>[  ] Grade E: Poor</td>
<td></td>
<td>BPG Search:</td>
<td>[ ] Major revision</td>
</tr>
</tbody>
</table>

COMMENTS TO AUTHORS
A nice review. It would be better to provide several figures to illustrate the resistance-associated pathways described in the text, which will greatly help readers and also increase citations.
ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Oncology
ESPS manuscript NO: 28882
Title: Targeted therapies in breast cancer: New challenges to fight against resistance
Reviewer's code: 00289387
Reviewer’s country: United States
Science editor: Fang-Fang Ji
Date sent for review: 2016-07-21 14:18
Date reviewed: 2016-08-04 21:38

<table>
<thead>
<tr>
<th>CLASSIFICATION</th>
<th>LANGUAGE EVALUATION</th>
<th>SCIENTIFIC MISCONDUCT</th>
<th>CONCLUSION</th>
</tr>
</thead>
<tbody>
<tr>
<td>[ ] Grade A: Excellent</td>
<td>[ ] Grade A: Priority publishing</td>
<td>[ ] The same title</td>
<td>[ ] Accept</td>
</tr>
<tr>
<td>[ ] Grade B: Very good</td>
<td>[ Y] Grade B: Minor language polishing</td>
<td>[ ] Duplicate publication</td>
<td>[ ] High priority for publication</td>
</tr>
<tr>
<td>[ Y] Grade C: Good</td>
<td>[ ] Grade C: A great deal of language polishing</td>
<td>[ ] Plagiarism</td>
<td>[ ] Rejection</td>
</tr>
<tr>
<td>[ ] Grade D: Fair</td>
<td>[ ] Grade D: Rejected</td>
<td>[ Y] No</td>
<td>[ ] Minor revision</td>
</tr>
<tr>
<td>[ ] Grade E: Poor</td>
<td>BPG Search:</td>
<td></td>
<td>[ Y] Major revision</td>
</tr>
</tbody>
</table>

COMMENTS TO AUTHORS
The authors reviewed and summarized drug resistance of current breast cancer therapy. The manuscript primarily focus on the potential resistance mechanisms of breast cancer cells cultured in vitro, based on targeting breast cancer cells expressing growth factor receptors (e.g. EGFR, HER2). For broad interest of readers, relatively detailed info of clinical trials treated in different subtypes and stages of breast cancer should be provided. Such data shown in a table would be more informative, if any. In addition, the paper at the end also needs a short section of the future challenges. A precise percent of triple negative breast cancer population must be added prior to about 85% of breast tumor (p17), clarifying this rare specific type and avoiding confusion. The rationale for using anti-angiogenic therapy (e.g. sunitinib p18) in triple negative breast cancer was missing. A few grammatical errors must be corrected, such as adding "of" following one p6, ",," following breast p11 etc.
ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Oncology
ESPS manuscript NO: 28882
Title: Targeted therapies in breast cancer: New challenges to fight against resistance
Reviewer’s code: 00505881
Reviewer’s country: United States
Science editor: Fang-Fang Ji
Date sent for review: 2016-07-21 14:18
Date reviewed: 2016-08-09 05:48

CLASSIFICATION

[ ] Grade A: Excellent
[Y] Grade B: Very good
[ ] Grade C: Good
[ ] Grade D: Fair
[ ] Grade E: Poor

LANGUAGE EVALUATION

[ ] Grade A: Priority publishing
[Y] Grade B: Minor language polishing
[ ] Grade C: A great deal of language polishing
[ ] Grade D: Rejected

SCIENTIFIC MISCONDUCT

Google Search:
[ ] The same title
[ ] Duplicate publication
[ ] Plagiarism
[Y] No

BPG Search:
[ ] The same title
[ ] Duplicate publication
[ ] Plagiarism
[Y] No

CONCLUSION

[ ] Accept
[Y] High priority for publication
[ ] Rejection
[Y] Minor revision
[ ] Major revision

COMMENTS TO AUTHORS

This is a well-written review about recent developments in targeted therapies of breast cancer. This review covers what it promises to. The authors do a solid job of explaining the basics of breast cancer-targeted therapies. Along with the addition of the resistance in breast cancer-targeted therapies, the authors provide a good resource for readers who are more unfamiliar with resistance mechanisms but also provide detail. Minor concerns: 1. Brief diagrams or drawings on the action and resistance mechanisms of the targeted therapies are helpful. 2. An overall breast cancer-targeted therapies is needed. 3. Breast cancer combination therapy is a future direction in the field. The authors may strength this discussion.
ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Oncology
ESPS manuscript NO: 28882
Title: Targeted therapies in breast cancer: New challenges to fight against resistance
Reviewer’s code: 02959534
Reviewer’s country: China
Science editor: Fang-Fang Ji
Date sent for review: 2016-07-21 14:18
Date reviewed: 2016-08-26 22:04

<table>
<thead>
<tr>
<th>CLASSIFICATION</th>
<th>LANGUAGE EVALUATION</th>
<th>SCIENTIFIC MISCONDUCT</th>
<th>CONCLUSION</th>
</tr>
</thead>
<tbody>
<tr>
<td>[ ] Grade A: Excellent</td>
<td>[ ] Grade A: Priority publishing</td>
<td>[ ] The same title</td>
<td>[ ] Accept</td>
</tr>
<tr>
<td>[ ] Grade B: Very good</td>
<td>[ Y] Grade B: Minor language polishing</td>
<td>[ ] Duplicate publication</td>
<td>[ ] High priority for publication</td>
</tr>
<tr>
<td>[ ] Grade C: Good</td>
<td>[ ] Grade C: A great deal of language polishing</td>
<td>[ ] Plagiarism</td>
<td>[ ] Rejection</td>
</tr>
<tr>
<td>[ Y] Grade D: Fair</td>
<td>[ ] Grade D: Rejected</td>
<td>[Y ] No</td>
<td>[ ] Minor revision</td>
</tr>
<tr>
<td>[ ] Grade E: Poor</td>
<td></td>
<td></td>
<td>[ Y] Major revision</td>
</tr>
</tbody>
</table>

Google Search: [ ] The same title
Duplicate publication [ ] Plagiarism
BPG Search: [ ] The same title
Duplicate publication [ ] Plagiarism
[ Y] No

COMMENTS TO AUTHORS

The MS was to make a general overview of the current knowledge in the field of the mechanisms of resistance to targeted therapies in breast cancer. 1. The MS was well written; however, the mechanisms presented in this manuscript was too simple. 2. The indications of each targeted therapy was not described, and they are very important.